Show simple item record

dc.contributor.authorSaunders, R
dc.contributor.authorCohen, ZD
dc.contributor.authorAmbler, G
dc.contributor.authorDeRubeis, RJ
dc.contributor.authorWiles, N
dc.contributor.authorKessler, D
dc.contributor.authorGilbody, S
dc.contributor.authorHollon, SD
dc.contributor.authorKendrick, T
dc.contributor.authorWatkins, E
dc.contributor.authorRichards, D
dc.contributor.authorBrabyn, S
dc.contributor.authorLittlewood, E
dc.contributor.authorSharp, D
dc.contributor.authorLewis, G
dc.contributor.authorPilling, S
dc.contributor.authorBuckman, JEJ
dc.date.accessioned2022-07-27T09:05:52Z
dc.date.issued2021-12-04
dc.date.updated2022-07-27T08:26:12Z
dc.description.abstractBACKGROUND: Subgrouping methods have the potential to support treatment decision making for patients with depression. Such approaches have not been used to study the continued course of depression or likelihood of relapse following treatment. METHOD: Data from individual participants of seven randomised controlled trials were analysed. Latent profile analysis was used to identify subgroups based on baseline characteristics. Associations between profiles and odds of both continued chronic depression and relapse up to one year post-treatment were explored. Differences in outcomes were investigated within profiles for those treated with antidepressants, psychological therapy, and usual care. RESULTS: Seven profiles were identified; profiles with higher symptom severity and long durations of both anxiety and depression at baseline were at higher risk of relapse and of chronic depression. Members of profile five (likely long durations of depression and anxiety, moderately-severe symptoms, and past antidepressant use) appeared to have better outcomes with psychological therapies: antidepressants vs. psychological therapies (OR (95% CI) for relapse = 2.92 (1.24-6.87), chronic course = 2.27 (1.27-4.06)) and usual care vs. psychological therapies (relapse = 2.51 (1.16-5.40), chronic course = 1.98 (1.16-3.37)). CONCLUSIONS: Profiles at greater risk of poor outcomes could benefit from more intensive treatment and frequent monitoring. Patients in profile five may benefit more from psychological therapies than other treatments.en_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipMQ Foundationen_GB
dc.description.sponsorshipNational Institute for Health Researchen_GB
dc.description.sponsorshipHigher Education Funding Council for Englanden_GB
dc.description.sponsorshipRoyal College of Psychiatristsen_GB
dc.description.sponsorshipUniversity College Londonen_GB
dc.description.sponsorshipVanderbilt Universityen_GB
dc.description.sponsorshipUniversity of Southamptonen_GB
dc.description.sponsorshipUniversity of Exeteren_GB
dc.description.sponsorshipUniversity of Yorken_GB
dc.description.sponsorshipNIHR Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trusten_GB
dc.description.sponsorshipUniversity of Bristolen_GB
dc.format.extent1295-
dc.format.mediumElectronic
dc.identifier.citationVol. 11, No. 12, article 1295en_GB
dc.identifier.doihttps://doi.org/10.3390/jpm11121295
dc.identifier.grantnumber201292/Z/16/Zen_GB
dc.identifier.grantnumberMQDS16/72en_GB
dc.identifier.urihttp://hdl.handle.net/10871/130406
dc.identifierORCID: 0000-0002-8821-5027 (Richards, David)
dc.identifierResearcherID: B-4807-2009 (Richards, David)
dc.language.isoenen_GB
dc.publisherMDPIen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/34945767en_GB
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_GB
dc.subjectdepressionen_GB
dc.subjectlatent profile analysisen_GB
dc.subjectpatient stratificationen_GB
dc.subjectpersonalised medicineen_GB
dc.subjectprimary careen_GB
dc.titleA patient stratification approach to identifying the likelihood of continued chronic depression and relapse following Treatment for depression.en_GB
dc.typeArticleen_GB
dc.date.available2022-07-27T09:05:52Z
dc.identifier.issn2075-4426
exeter.article-numberARTN 1295
exeter.place-of-publicationSwitzerland
dc.descriptionThis is the final version. Available from MDPI via the DOI in this record.en_GB
dc.descriptionData Availability Statement: Requests for sharing of the IPD used in this study can be made to the corresponding author, any sharing of data will be subject to obtaining appropriate agreements from the chief investigators or data custodians for each individual trial dataset used here.en_GB
dc.identifier.journalJournal of Personalized Medicineen_GB
dc.relation.ispartofJ Pers Med, 11(12)
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2021-11-17
dc.rights.licenseCC BY
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2021-12-04
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-07-27T08:58:57Z
refterms.versionFCDVoR
refterms.dateFOA2022-07-27T09:05:53Z
refterms.panelAen_GB
refterms.dateFirstOnline2021-12-04


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's licence is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).